1 / 1

10 studies (N=686 participants) included.

Catch 22: Is the future of systematic reviewing only for the experienced? Mahesh Jayaram 1 , Kai Koch 2 ,  Kamel Mansi 3 , Euan Haynes 3 , Clive E Adams 3 , Vivek A Furtado 4 1 University of Melbourne

Download Presentation

10 studies (N=686 participants) included.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Catch 22: Is the future of systematic reviewing only for the experienced? Mahesh Jayaram1, Kai Koch2, Kamel Mansi3, Euan Haynes3, Clive E Adams3, Vivek A Furtado4 1University of Melbourne , 2 School of Medicine, University of Nottingham, UK3Cochrane Schizophrenia Group, University of Nottingham, Nottingham, UK4Forensic Psychiatry, Rampton Hospital, Retford, UK Introduction Results of the review • 10 studies (N=686 participants) included. • Clinical improvement in clinical global state at short term (< 3months) and medium term (3 -6 months)(evidence quality - low) • Fewer people receiving trifluoperazine left studies early due to relapse or worsening at medium term (2 RCTs, n=381, RR 0.34 CI 0.23 to 0.49, very low quality evidence). • No difference between trifluoperazine and placebo for outcome of leaving the study early any reason/due to severe adverse effects (medium term). • For economic outcomes, we valued outcomes for relapse and hospital discharge and presented them in additional tables (Grade C level of economic data from trials reporting limited information). • Increasingly, calls are made for those undertaking systematic reviews to have highly specialist knowledge in the field. • Some Cochrane groups prefer authors with previous experience of conducting reviews or statistical background. • ….so, experience cannot be gained except by those with experience. • The existing cohort of reviewers are getting older, there is lots of work to be done and we need young energetic reviewers! Outcome: Global state - Clinical improvement (as defined by each study) Aims • To investigate whether motivated but inexperienced people, with a bit of support and training, follow a structured template and produce a high quality Cochrane review. Materials Economic outcomes: Sensitivity analysis* Free online training* Enthusiastic Medical Student, Research assistant & a school leaver Cochrane Schizophrenia Group Straightforward review topic Published in Cochrane Library Trifluoperazine vs Placebo for Schizophrenia 153.4 days, 216 days, 3£338, 4£299, 5£376*Unlike the effectiveness data of this review, the included economic studies have not been weighted according to sample size; hence risk ratios (RR) of cost of relapse for the study population (if calculated) may not be equal to the RR as calculated by RevMan.**Cost attributed to each individual participant within each arm of the trial, irrespective of whether they relapsed or not. Discussion * For free online training visit: https://sites.google.com/site/revmantutorial1/ • Lots of high quality reviews can be conducted by those with interest, who may not have a lot of experience but gain it in the process. • These can be done relatively quickly. • A supportive environment is necessary but is available within the Collaboration. • Results of the review show that trifluoperazine is an effective drug compared to placebo for treating schizophrenia. • The unit cost of relapse is a novel way of calculating economic costs. Results of the project • The students need some help in understanding the process, data extraction, clinical application and write up. This took approximately 8 hours of one experienced reviewers time (CEA). • The review was completed in 1 month (excluding editing time) • Medical student (KK) now in final year of medical school. School student (EH) gained entry into medical school and KM gained lectureship in a leading UK university. • VF provided economic analysis and MJ edited the review. • The review process was helpful to the students. References 1. Heller J. Catch-22 / Joseph Heller. London: Corgi; 1974. 2. Koch K, Mansi K, Haynes E, Adams CE, Furtado V. Trifluoperazine versus placebo for schizophrenia. Cochrane Database Systematic Reviews 2013 (in press)

More Related